<?xml version="1.0" encoding="UTF-8" standalone="no"?><information><Cell><NavigationPath><Head00>Variable</Head00><Stub><StubValue>Pain</StubValue></Stub><HeaderValue>Time compared with</HeaderValue></NavigationPath><value>As above</value><CellType>Text</CellType></Cell><Table><TableType>Matrix</TableType><tableName>Secondary outcome parameters.</tableName><tableOrder>Table 2</tableOrder><tableFooter>A: Patients with placebo and patients with IVIG, B: Patients post crossover and same patients before crossover, α: Average of values from study day 13–19 and average of values during 7 days before termination/ completion of study, β: First two weeks following (main or crossover) treatment and last two weeks before the end of (main or crossover) study for a particular patient, PACIS: one time point measurement at day 14 following treatment and at the day of the end of (main or crossover) study. PGIC: Patient Global Impression of Change Scale [17]; SF-36: Medical Outcomes Study 36-Item Short Form [18]; COOP/WONCA: Dartmouth Primary Care Cooperative Information Project charts for adults [19]; PACIS: Perceived Adjustment to Chronic Illness Scale [20].</tableFooter></Table><Document><DocumentTitle>Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: a study protocol[ISRCTN33042138]</DocumentTitle><PMC>149450</PMC></Document></information>